Granted Patent
B1
US 12,503,702 · App. 18/896,055 · Granted Dec 23, 2025
Composition for regulating production of interfering ribonucleic acid
Assignee:
Wyvern Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule, such as SGLT-2. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to expression of the target biomolecule.
Claims (3)
1 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is 100% identical to SEQ ID NO. 2.
2 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is 100% identical to SEQ ID NO. 3.
3 . The composition of claim 1 , wherein the RP is encased in a protein coat, a lipid vesicle, or any combination thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 9, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072520/0302 →
References Cited (38)
US 8362232B2
· Bhanot
· 2013
[cited by examiner]
CA 2721333A1
· 2009
[cited by applicant]
Pfeifer, A. and Verma, I.M. “Gene Therapy: Promises and Problems”. Annual Reviews in Genomics Human Genetics, vol. 2 (2001), pp. 177-211 (Year: 2001).
[cited by examiner]
Zhang, X. et al. “MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer”. International Journal of Oncology, vol. 54 (2019), pp. 199-208 (Year: 2019).
[cited by examiner]
Ren, D. et al. “SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis”. Cancer Letters, vol. 519 (2021), pp. 277-288.. (Year: 2021).
[cited by examiner]
Supplemental Data pdf—Ren, D. et al. “SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis”. Cancer Letters, vol. 519 (2021), pp. 277-288. (Year: 2021).
[cited by examiner]
Feng, J. et al. “Pro-angiogenic microRNA-296 upregulates vascular endothelial growth factor and downregulates Notch1 following cerebral ischemic injury”. Molecular Medicine Reports, vol. 12, (2015), pp. 8141-8147 (Year:…
[cited by examiner]
O'Brien, et al. “Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation.” Front Endocrinol (Lausanne), (2018) 9:402, p. 1-12. (Year: 2018).
[cited by examiner]
Gorski, S., Vogel, J. & Doudna, J. “RNA-based recognition and targeting_ sowing the seeds of specificity”. Nat Rev Mol Cell Biol 18 (2017), 215-228. (Year: 2017).
[cited by examiner]
Lam et al. “siRNA Versus miRNA as Therapeutics for Gene Silencing”. Molecular Therapy. Nucleic Acids. vol. 4 (2015) pp. e252-e252. (Year: 2015).
[cited by examiner]
Ying et al.“The MicroRNA (miRNA): Overview of the RNA Genes that Modulate Gene Function”. Mol. Biotechnol. (2008) 38:257-268. (Year: 2008).
[cited by examiner]
Van den Berg, et al. “Design of Effective Primary MicroRNA Mimics With Different Basal Stem Conformations”. Molecular Therapy—Nucleic Acids, vol. 5 (2016), pp. 1-12. (Year: 2016).
[cited by examiner]
Denzler R et al.“Impact of MicroRNA Levels, Target-Site Complementarity, and Cooperativity on Competing Endogenous RNA-Regulated Gene Expression.” Mol Cell. Nov. 3, 2016;64(3):565-579. (Year: 2016).
[cited by examiner]
Bottoni et al. “Targeting BTK through microRNA in chronic lymphocytic leukemia.” Blood, The Journal of the American Society of Hematology 128.26 (2016): 3101-3112.
[cited by applicant]
Christensen et al. “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848.
[cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166.
[cited by applicant]
Tritschler et al. “Concepts and limitations for learning developmental trajectories from single cell genomics.” Development 146.12 (2019): dev170506.
[cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253.
[cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494.
[cited by applicant]
Clark et al. “Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.” Oncotarget 11.44 (2020): 4016.
[cited by applicant]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery.” Nature reviews Drug discovery 18.5 (2019): 358-378.
[cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675.
[cited by applicant]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (2010).
[cited by applicant]
Brutons Tyrosine Kinase Genbank Sequence (2023).
[cited by applicant]
GenBank EGFR Sequence (2023).
[cited by applicant]
GenBank EGF Sequence (2023).
[cited by applicant]
NCBI search results for Seq Id No. 5 (2024).
[cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023).
[cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023).
[cited by applicant]
NCBI Nucleotide Sequence for PARP, search performed Dec. 26, 2024 (2024).
[cited by applicant]
GenBank FLT3 Sequence (2024).
[cited by applicant]